skip to content »

Neurology - Alzheimers

Houston, Texas

The Cullen Building at Baylor College of Medicine.
Department of Neurology
not shown on screen

Past Clinical Trials

Cholinesterase Inhibitors

  • "A Double-Blind Placebo-Controlled Parallel-Group Multicenter Study of Tacrine (CI-970-61) with Doses up to 160 mg/day in Patients with Alzheimer's Disease," and Open-Label Extension Study, Parke-Davis, 1991-1995
  • "A Preliminary Multicenter Randomized Double-Blind Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer's Disease," and Open-Label Extension Study (201/202), Eisai America, 1991-1997
  • "A 15-Week Multicenter Randomized Double-Blind Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer's Disease," and Open-Label Extension Study (301/303), Eisai America, 1994-1998
  • "A 54-Week Randomized Double-Blind Placebo-Controlled Evaluation of the Effects of Donepezil Hydrochloride (E2020) on Functional Outcomes in Patients with Alzheimer's Disease with a Staged Crossover to Open-Label Donepezil," and Open-Label Extension Study (E2020-A001-312/314), Eisai America, 1996-1998
  • "An Open-Label Study to Evaluate the Safety and Efficacy of 1/5 mg b.i.d. (3mg/day) through 6 mg b.i.d. (12mg/day) Exelon in Patients with Probable Alzheimer's Disease in the Community Setting", Novartis, 1997-2000
  • "A 24-Week Multicenter Randomized Double-Blind Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Patients with Dementia Associated with Cerebrovascular Disease" (E2020-A001-308/309), Eisai, 1998-2001
  • "A Single-Center Randomized Double-Blind Placebo-Controlled Pilot Study of the Safety and Tolerability of 15 and 20 mg Donepezil Hydrochloride in Patients with Mild to Moderate Alzheimer's Disease Treated with Aricept 10 mg daily", Pfizer/Eisai, 2001-2003
  • "The Efficacy of Controlled-Release Oral Physostigmine in Alzheimer's Disease and Senile Dementia of the Alzheimer's Type" Forest Laboratories, 1989-1992

Other Cholinergic Therapies

  • "A 12-Week Double-Blind Placebo-Controlled Parallel-Group Dose-Response Multicenter Study of CI-979 in Patients with Alzheimer's Disease," and Open-Label Extension Study, Parke-Davis, 1993-1996
  • "A Randomized Double-Blind Placebo-Controlled Dose-Ranging Study of the Efficacy and Tolerability of SB202026 in Patients Suffering From Dementia of the Alzheimer's Type," and Open-Label Extension Study (007), SmithKline Beecham, 1994-1998
  • "A 26-Week Randomized Double-Blind Placebo-Controlled Parallel-Group Multicenter Study of Milameline (C1979/RU35926) in Patients with Probable Alzheimer's Disease," and Open-Label Extension Study, Parke-Davis, 1996-1997
  • "A 24-Week Double-Blind Placebo-Controlled Parallel-Group Fixed-Dose Study of the Efficacy and Tolerability of SB202026 25ug b.i.d. and SB202026 50ug o.d. in Patients Suffering from Dementia of the Probable Alzheimer's Type," and Open-Label Extension Study (045/050), SmithKline Beecham, 1996-1998
  • "Randomized Double-Blind Placebo-Controlled Four-Arm Dose-Finding Study Investigating the Efficacy and Safety of Three Doses of LU-25-109 in Patients with Alzheimer's Disease", Lundbeck, 1997-1999.
  • "Efficacy and Safety of 6, 12, 24, and 36 mg t.i.d. po and 36 mg b.i.d. po Talsaclidine (free base) for 12 Weeks in a Double-Blind Randomized Placebo-Controlled Group Comparison in Patients with Mild to Moderate Dementia of the Alzheimer's Type", Boehringer Ingelheim, 1999-2000
  • "Phase III 12-Week Randomized Double-Blind Placebo-Controlled Multicenter Study Evaluating the Safety and Efficacy of Three Fixed Doses of Oral CP-457, 920 (30 mg q.d., 60 mg b.i.d., 120 mg b.i.d.) and Donepezil in Outpatients with Alzheimer's Disease", Pfizer, 2001-2003

Non-Cholinergic Therapies

  • "Alzheimer's Disease Co-Operative Study Unit, Selegiline/Tocopherol Study" National Institute of Health (NIH), 1992-1994
  • "Alzheimer's Disease Co-Operative Study Unit, Multicenter Evaluation of New Treatment Efficacy Measures", National Institute of Health (NIH), 1993-1994
  • "A Controlled Study of Ondansetron in the Treatment of Primary Degenerative Dementia of the Alzheimer's Type," and Open-Label Extension Study, Glaxo Inc., 1993-1996
  • "Alzheimer's Disease Co-Operative Study Unit, Estrogen Study" National Institute of Health (NIH), 1997-1999
  • "Alzheimer's Disease Co-Operative Study Unit, Melatonin Study" National Institute of Health (NIH), 1997-1999
  • "Efficacy and Long-Term Tolerability of Memantine in Patients with Moderately Severe to Severe Alzheimer's Disease (AD)", Merz, 1998-1999
  • "Alzheimer's Disease Co-Operative Study Unit, Mild Cognitive Impairment Study" National Institute of Health (NIH), 1998-2003
  • "A 24-Week Multicenter Parallel-Group Double-Blind Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Estrogen in the Treatment of Alzheimer's Disease in Outpatients Treated with Donepezil", Pfizer, 1999-2001
  • "Alzheimer's Disease Co-Operative Study Unit, Rofecoxib/Naproxen Study" National Institute of Health (NIH), 2000-2002
  • "A Randomized Double-Blind Safety, Tolerability, Immunogenicity, and Pilot Efficacy Study of AN 1792 (QS-21) in Patients with Mild to Moderate Alzheimer's Disease", Elan, 2001-2003
  • "A Randomized Double-Blind Placebo Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Mild to Moderate Dementia of the Alzheimer's Type", Forest labs, 2002-2003

E-mail this page to a friend